Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 204

1.

The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic.

Frankell AM, Jammula S, Li X, Contino G, Killcoyne S, Abbas S, Perner J, Bower L, Devonshire G, Ococks E, Grehan N, Mok J, O'Donovan M, MacRae S, Eldridge MD, Tavaré S; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium, Fitzgerald RC.

Nat Genet. 2019 Feb 4. doi: 10.1038/s41588-018-0331-5. [Epub ahead of print]

PMID:
30718927
2.

No Association Between Vitamin D Status and Risk of Barrett's Esophagus or Esophageal Adenocarcinoma-a Mendelian Randomization Study.

Dong J, Gharahkhani P, Chow WH, Gammon MD, Liu G, Caldas C, Wu AH, Ye W, Onstad L, Anderson LA, Bernstein L, Pharoah PD, Risch HA, Corley DA, Fitzgerald RC; Stomach and Esophageal Cancer Study (SOCS) Consortium, Iyer PG, Reid BJ, Lagergren J, Shaheen NJ, Vaughan TL, MacGregor S, Love S, Palles C, Tomlinson I, Gockel I, May A, Gerges C, Anders M, Böhmer AC, Becker J, Kreuser N, Thieme R, Noder T, Venerito M, Veits L, Schmidt T, Schmidt C, Izbicki JR, Hölscher AH, Lang H, Lorenz D, Schumacher B, Mayershofer R, Vashist Y, Ott K, Vieth M, Weismüller J, Nöthen MM, Moebus S, Knapp M, Peters WHM, Neuhaus H, Rösch T, Ell C, Jankowski J, Schumacher J, Neale RE, Whiteman DC, Thrift AP.

Clin Gastroenterol Hepatol. 2019 Feb 1. pii: S1542-3565(19)30088-6. doi: 10.1016/j.cgh.2019.01.041. [Epub ahead of print]

PMID:
30716477
3.

Early detection and therapeutics.

Januszewicz W, Fitzgerald RC.

Mol Oncol. 2019 Jan 24. doi: 10.1002/1878-0261.12458. [Epub ahead of print] Review.

4.

Author Correction: Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1.

Garcia E, Hayden A, Birts C, Britton E, Rogerson C, Bleaney CW, Cowie A, Pickard K, Mellone M, Choh C, Derouet M, Duriez P, Noble F, White MJ, Primrose JN, Strefford JC, Rose-Zerilli M, Thomas GJ, Ang Y, Sharrocks AD, Fitzgerald RC, Underwood TJ; OCCAMS consortium.

Sci Rep. 2019 Jan 22;9(1):318. doi: 10.1038/s41598-018-37591-7.

5.

A biomarker panel predicts progression of Barrett's esophagus to esophageal adenocarcinoma.

Duits LC, Lao-Sirieix P, Wolf WA, O'Donovan M, Galeano-Dalmau N, Meijer SL, Offerhaus GJA, Redman J, Crawte J, Zeki S, Pouw RE, Chak A, Shaheen NJ, Bergman JJGHM, Fitzgerald RC.

Dis Esophagus. 2019 Jan 1;32(1). doi: 10.1093/dote/doy102.

PMID:
30496496
6.

Somatic mutant clones colonize the human esophagus with age.

Martincorena I, Fowler JC, Wabik A, Lawson ARJ, Abascal F, Hall MWJ, Cagan A, Murai K, Mahbubani K, Stratton MR, Fitzgerald RC, Handford PA, Campbell PJ, Saeb-Parsy K, Jones PH.

Science. 2018 Nov 23;362(6417):911-917. doi: 10.1126/science.aau3879. Epub 2018 Oct 18.

PMID:
30337457
7.

DNA Methylation Biomarkers for the Diagnosis of Barrett's Oesophagus.

Kosmidou C, Jammula S, Fitzgerald RC.

Am J Gastroenterol. 2018 Nov;113(11):1722. doi: 10.1038/s41395-018-0226-1. Epub 2018 Oct 17. No abstract available.

PMID:
30333547
8.

A crosssectional analysis of Facebook comments to study public perception of a new diagnostic test called the Cytosponge.

Tan WK, Muldrew B, Khan Z, Fitzgerald RC.

Dis Esophagus. 2019 Jan 1;32(1). doi: 10.1093/dote/doy085.

PMID:
30239646
9.

Identification of Prognostic Phenotypes of Esophageal Adenocarcinoma in 2 Independent Cohorts.

Sawas T, Killcoyne S, Iyer PG, Wang KK, Smyrk TC, Kisiel JB, Qin Y, Ahlquist DA, Rustgi AK, Costa RJ, Gerstung M, Fitzgerald RC, Katzka DA; OCCAMS Consortium.

Gastroenterology. 2018 Dec;155(6):1720-1728.e4. doi: 10.1053/j.gastro.2018.08.036. Epub 2018 Aug 27.

PMID:
30165050
10.

Safety and Acceptability of a Nonendoscopic Esophageal Sampling Device - Cytosponge: A Systematic Review of Multicenter Data.

Januszewicz W, Tan WK, Lehovsky K, Debiram-Beecham I, Nuckcheddy T, Moist S, Kadri S, di Pietro M, Boussioutas A, Shaheen NJ, Katzka DA, Dellon ES, Fitzgerald RC; BEST1 and BEST2 study investigators.

Clin Gastroenterol Hepatol. 2018 Aug 9. pii: S1542-3565(18)30809-7. doi: 10.1016/j.cgh.2018.07.043. [Epub ahead of print]

PMID:
30099104
11.

MUC16 Mutations and Prognosis in Gastric Cancer: A Little Goes a Long Way.

Smyth EC, Fitzgerald RC.

JAMA Oncol. 2018 Dec 1;4(12):1698-1699. doi: 10.1001/jamaoncol.2018.2803. No abstract available.

PMID:
30098141
12.

Acceptability, Accuracy, and Safety of Disposable Transnasal Capsule Endoscopy for Barrett's Esophagus Screening.

Sami SS, Iyer PG, Pophali P, Halland M, di Pietro M, Ortiz-Fernandez-Sordo J, White JR, Johnson M, Guha IN, Fitzgerald RC, Ragunath K.

Clin Gastroenterol Hepatol. 2018 Aug 3. pii: S1542-3565(18)30743-2. doi: 10.1016/j.cgh.2018.07.019. [Epub ahead of print]

13.

Barrett's oESophagus trial 3 (BEST3): study protocol for a randomised controlled trial comparing the Cytosponge-TFF3 test with usual care to facilitate the diagnosis of oesophageal pre-cancer in primary care patients with chronic acid reflux.

Offman J, Muldrew B, O'Donovan M, Debiram-Beecham I, Pesola F, Kaimi I, Smith SG, Wilson A, Khan Z, Lao-Sirieix P, Aigret B, Walter FM, Rubin G, Morris S, Jackson C, Sasieni P, Fitzgerald RC; BEST3 Trial team.

BMC Cancer. 2018 Aug 3;18(1):784. doi: 10.1186/s12885-018-4664-3.

14.

Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics.

Li X, Francies HE, Secrier M, Perner J, Miremadi A, Galeano-Dalmau N, Barendt WJ, Letchford L, Leyden GM, Goffin EK, Barthorpe A, Lightfoot H, Chen E, Gilbert J, Noorani A, Devonshire G, Bower L, Grantham A, MacRae S, Grehan N, Wedge DC, Fitzgerald RC, Garnett MJ.

Nat Commun. 2018 Jul 30;9(1):2983. doi: 10.1038/s41467-018-05190-9.

15.

Screening for Barrett's Esophagus: Are New High-Volume Methods Feasible?

O'Donovan M, Fitzgerald RC.

Dig Dis Sci. 2018 Jul 11. doi: 10.1007/s10620-018-5192-3. [Epub ahead of print] Review.

16.

Selection and Application of Tissue microRNAs for Nonendoscopic Diagnosis of Barrett's Esophagus.

Li X, Kleeman S, Coburn SB, Fumagalli C, Perner J, Jammula S, Pfeiffer RM, Orzolek L, Hao H, Taylor PR, Miremadi A, Galeano-Dalmau N, Lao-Sirieix P, Tennyson M, MacRae S, Cook MB, Fitzgerald RC.

Gastroenterology. 2018 Sep;155(3):771-783.e3. doi: 10.1053/j.gastro.2018.05.050. Epub 2018 Jun 12.

17.

Organ-preserving approaches in oesophageal cancer.

Fitzgerald RC.

Lancet Oncol. 2018 Jul;19(7):858-859. doi: 10.1016/S1470-2045(18)30291-2. Epub 2018 Jun 1. No abstract available.

18.

Glucose transporter 1 expression as a marker of prognosis in oesophageal adenocarcinoma.

Blayney JK, Cairns L, Li G, McCabe N, Stevenson L, Peters CJ, Reid NB, Spence VJ, Chisambo C, McManus D, James J, McQuaid S, Craig S, Arthur K, McArt D, Ong CJ, Lao-Sirieix P, Hamilton P, Salto-Tellez M, Eatock M, Coleman HG, Fitzgerald RC, Kennedy RD, Turkington RC; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Study Group.

Oncotarget. 2018 Apr 6;9(26):18518-18528. doi: 10.18632/oncotarget.24906. eCollection 2018 Apr 6.

19.

Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study.

Fewings E, Larionov A, Redman J, Goldgraben MA, Scarth J, Richardson S, Brewer C, Davidson R, Ellis I, Evans DG, Halliday D, Izatt L, Marks P, McConnell V, Verbist L, Mayes R, Clark GR, Hadfield J, Chin SF, Teixeira MR, Giger OT, Hardwick R, di Pietro M, O'Donovan M, Pharoah P, Caldas C, Fitzgerald RC, Tischkowitz M.

Lancet Gastroenterol Hepatol. 2018 Jul;3(7):489-498. doi: 10.1016/S2468-1253(18)30079-7. Epub 2018 Apr 27.

20.

New Screening Techniques in Barrett's Esophagus: Great Ideas or Great Practice?

Spechler SJ, Katzka DA, Fitzgerald RC.

Gastroenterology. 2018 May;154(6):1594-1601. doi: 10.1053/j.gastro.2018.03.031. Epub 2018 Mar 23. Review. No abstract available.

PMID:
29577931

Supplemental Content

Loading ...
Support Center